Posts

Italy opened its vaccination campaign against monkeypox on Monday, as case numbers have increased at a time when health authorities are reporting vaccine shortages worldwide.

The United States declared monkeypox a public health emergency last week, an effort to bolster the U.S. response to contain the outbreak. The virus continues to be largely transmitted among gay and bisexual men, but experts say the disease could spill over into other populations, especially due to vaccine shortages.

President Joe Biden has appointed two top federal officials to coordinate his administration’s response to monkeypox, the White House said on Tuesday, as more states declared emergencies to help boost vaccines and other resources to combat the virus.

The U.S. Centers for Disease Control and Prevention (CDC) said on Wednesday it plans to make the rapidly spreading monkeypox disease a nationally notifiable condition.

There have been more than 18,000 cases of monkeypox reported globally from 78 countries, with the majority in Europe, the World Health Organization said on Wednesday.

Drugmaker Bavarian Nordic said U.S. and European regulators have approved the use of Jynneos vaccine doses made at the company’s plant in Denmark as global efforts to tackle the monkeypox outbreak pick up pace.

Scientists advising the World Health Organization (WHO) on monkeypox say the window is closing to stop its spread, with cases currently doubling every two weeks, raising concerns that it will take several months for the outbreak to peak.

The European Commission urged the 27 EU members on Wednesday to take a more forceful and coordinated approach towards monkeypox now that the World Health Organization has declared it a global health emergency.

Over the weekend, the World Health Organization declared the monkeypox outbreak, so far documented in more than 70 countries, a “public health emergency of international concern [PHEIC].” Here are the initiatives some biopharma companies are taking to contain monkeypox.

Bavarian Nordic, the Danish company behind the vaccine being used to try to stem a global outbreak of monkeypox, is in talks to potentially expand production capacity, its CEO said on Monday.